Drug Trial Radar · NCT04998201
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
353
Actual
Start
Sep 28, 2021
Primary completion
Feb 10, 2023
Study completion Aug 14, 2023
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Aug 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.
Conditions
- Mixed Dyslipidemia
Interventions
ARO-APOC3Drug
ARO-APOC3 Injection
PlaceboDrug
Sterile Normal Saline (0.9% NaCl)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline at Week 24 in Fasting TGTime frame: Baseline, Week 24
Locations
30 sites in 6 countries. Site status is shown where the registry gives one.
Research Site 3
Beverly Hills, California
Research Site 8
Northridge, California
Research Site 2
Boca Raton, Florida
Research Site 1
Fort Lauderdale, Florida
Research Site 14
Miami Springs, Florida
Research Site 5
Pembroke Pines, Florida
Research Site 18
Dunwoody, Georgia
Research Site 31
Las Vegas, Nevada
Research Site 17
New Windsor, New York
Research Site 12
Dayton, Ohio
Research Site 4
Franklin, Ohio
Research Site 7
Greenville, South Carolina
Research Site 6
Houston, Texas
Research Site 32
Houston, Texas
Research Site 13
San Antonio, Texas
Research Site 30
Morayfield, Queensland, Australia
Research Site 29
Adelaide, South Australia, Australia
Research Site 19
Clayton, Victoria, Australia
Research Site 27
Joondalup, Western Australia, Australia
Research Site 15
Concord, Ontario, Canada
Research Site 10
Montreal, Quebec, Canada
Research Site 20
Balatonfüred, Hungary
Research Site 21
Debrecen, Hungary
Research Site 22
Nyíregyháza, Hungary
Research Site 11
Auckland, New Zealand
Research Site 16
Christchurch, New Zealand
Research Site 28
Lodz, Poland
Research Site 24
Lodz, Poland
Research Site 25
Poznan, Poland
Research Site 26
Rzeszów, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.